DNA Repair, Epigenetic, and Cytokine Crosstalk Drive Head and Neck Cancer Resistance: New Therapeutic Avenues Emerge

Head and Neck Cancer (HNC) is a formidable malignancy characterized by profound genomic instability, leading to significant therapeutic resistance and suboptimal survival outcomes, particularly in advanced-stage disease. Current standard-of-care treatments, often involving surgery, radiation, and chemotherapy, frequently encounter limitations due to the tumor's complex adaptive mechanisms. This review critically examines the mechanistic interplay between DNA damage response (DDR) pathways, epigenetic dysregulation, and cytokine-driven inflammatory networks. Understanding how these interconnected systems collectively impact HNC progression and therapeutic vulnerability is crucial for overcoming current treatment shortcomings and developing more effective, targeted interventions. The goal is to identify specific gaps in our current understanding that, once addressed, can lead to novel therapeutic strategies.

This comprehensive review aimed to critically examine the intricate mechanistic interplay among DNA damage response (DDR) pathways, epigenetic dysregulation, and cytokine-driven inflammatory networks within the context of Head and Neck Cancer (HNC). The authors synthesized findings from a broad range of recent preclinical and early clinical studies. Their methodology involved evaluating the collective impact of these interconnected biological processes on HNC progression, immune evasion, and the development of therapeutic resistance. A key objective was to identify and assess emerging therapeutic opportunities, including novel combination strategies and ongoing clinical trials, that specifically target these complex crosstalk mechanisms to enhance treatment efficacy and advance precision oncology.